Ontology highlight
ABSTRACT: Background
Type 2 diabetes mellitus has become one of the most important public health concerns worldwide. Due to its high prevalence and morbidity, there is an avid necessity to find new therapies that slow the progression and promote the regression of the disease. Imatinib mesylate is a tyrosine kinase inhibitor that binds to the Abelson tyrosine kinase and related proteins. It enhances ?-cell survival in response to toxins and pro-inflammatory cytokine. The aim of this study is to evaluate the effect of imatinib on fasting plasma glucose in subjects with normal fasting glucose, subjects with impaired fasting glucose and in subjects with type 2 diabetes mellitus.Methods
We identified 284 subjects diagnosed with chronic myeloid leukemia or gastrointestinal stromal tumors from the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran database. 106/284 subjects were treated with imatinib. We compared the effect of imatinib on fasting plasma glucose after 1 and 6 months of treatment. We used ANOVA test of repeated samples to determine statistical significance in fasting plasma glucose before imatinib treatment and the follow-up. Statistical analysis was performed with Statistical Package for the Social Sciences v22.Results
We included a total of 106 subjects: 76 with fasting plasma glucose concentrations ConclusionSubjects with chronic myeloid leukemia or gastrointestinal stromal tumor with type 2 diabetes mellitus had a significant reduction in fasting plasma glucose and glycosylated hemoglobin at 1 and 6 months while using imatinib.
SUBMITTER: Gomez-Samano MA
PROVIDER: S-EPMC6215634 | biostudies-literature | 2018 Nov
REPOSITORIES: biostudies-literature
Gómez-Sámano Miguel Ángel MÁ Baquerizo-Burgos Jorge Enrique JE Coronel Melissa Fabiola Coronel MFC Wong-Campoverde Buileng Daniela BD Villanueva-Martinez Fernando F Molina-Botello Diego D Avila-Rojo Jose Alonso JA Palacios-Báez Lucía L Cuevas-Ramos Daniel D Gomez-Perez Francisco Javier FJ Zentella-Dehesa Alejandro A Aguayo-González Álvaro Á Gulias-Herrero Alfonso A
BMC endocrine disorders 20181103 1
<h4>Background</h4>Type 2 diabetes mellitus has become one of the most important public health concerns worldwide. Due to its high prevalence and morbidity, there is an avid necessity to find new therapies that slow the progression and promote the regression of the disease. Imatinib mesylate is a tyrosine kinase inhibitor that binds to the Abelson tyrosine kinase and related proteins. It enhances β-cell survival in response to toxins and pro-inflammatory cytokine. The aim of this study is to eva ...[more]